Controversies in sepsis clinical trials: proceedings of a meeting of the International Sepsis Forum, Lausanne, Switzerland, September 29, 2001

Journal of Critical Care

Volumn 21, Issue 1, 2006, Pages 38-47

  Dellinger, R Phillip ^a,b   Abraham, Edward ^c   Bernard, Gordon ^d   Marshall, John C ^e,f   Vincent, Jean Louis ^f  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UMDNJ Robert Wood Johnson Medical School at Camden   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f ERASME HOSPITAL   (Belgium)

Author keywords

Drug development; International Sepsis Forum; Preclinical animal experimentation; Sepsis clinical trials

Indexed keywords

AFELIMOMAB; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CYTOKINE; DOPAMINE; DROTRECOGIN; ENDOTOXIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ARTICLE; ARTIFICIAL VENTILATION; CLINICAL PRACTICE; EXPERIMENTAL THERAPY; HEMORRHAGIC SHOCK; HIGH RISK PATIENT; HUMAN; LEUKOCYTOSIS; LOGISTIC REGRESSION ANALYSIS; MEDICAL EDUCATION; MEDICAL RESEARCH; NONHUMAN; ONCOLOGY; PERITONITIS; PNEUMONIA; PRACTICE GUIDELINE; SEPSIS; SWITZERLAND;

ANIMALS; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; LOGISTIC MODELS; SEPSIS; SWITZERLAND; THERAPIES, INVESTIGATIONAL;

EID: 33645974042     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2005.07.002     Document Type: Article

References (19)

1. Ohlsson K., Björk P., Bergenfeldt M., et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348 (1990) 550-552
2. Bodmer M., Fournel M.A., and Hinshaw L.B. Preclinical review of anti-tumor necrosis factor monoclonal antibodies. Crit Care Med 21 (1993) S441-S446
3. Otero-Anton E., Gonzalez-Quintela A., Lopez-Soto A., et al. Cecal ligation and puncture as a model of sepsis in the rat: influence of the puncture size on mortality, bacteremia, endotoxemia and tumor necrosis factor alpha levels. Eur Surg Res 33 (2001) 77-79
4. Remick D., Manohar P., Bolgos G., et al. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 4 (1995) 89-95
5. Marshall J.C. The effects of granulocyte colony-stimulating factor in preclinical models of infection and acute inflammation. Shock 24 Suppl 1 (2005) 120-129
6. Arndt P., and Abraham E. Immunological therapy of sepsis: experimental therapies. Intensive Care Med 27 Suppl 1 (2001) S104-S115
7. Esmon C.T. Why do animal models (sometimes) fail to mimic human sepsis?. Crit Care Med 32 (2004) S219-S222
8. The ARDS Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342 (2000) 1301-1308
9. Hebert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340 (1999) 409-417
10. 2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 32 (2004) 2173-2182
11. Quartin A.A., Schein R.M., Kett D.H., et al. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 277 (1997) 1058-1063
12. Marshall J.C., Cook D.J., Christou N.V., et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23 (1995) 1638-1652
13. Vincent J.L., Moreno R., Takala J., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22 (1996) 707-710
14. Bernard G.R., Doig B.G., Hudson G., Lemeshow S., Marshall S., Russell J.C., et al. Quantification of organ failure for clinical trials and clinical practice. [abstract]. Am J Respir Crit Care Med 151 (1995) A323
15. Kress J.P., Christenson J., Pohlman A.S., et al. Outcomes of critically ill cancer patients in a university hospital setting. Am J Respir Crit Care Med 160 (1999) 1957-1961
16. Vincent J.L., de Mendonça A., Cantraine F., et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicentric, prospective study. Crit Care Med 26 (1998) 1793-1800
17. Lopes Ferreira F., Peres Bota D., Bross A., et al. Serial evaluation of the SOFA score to predict outcome. JAMA 286 (2001) 1754-1758
18. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
19. Vincent J.L., Angus D.C., Artigas A., et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31 (2003) 834-840